In order to develop better treatments for patients with skeletal defects due to disrupted/deficient TGFβ signaling, such as patients with Loeys–Dietz Syndrome, Marfan Syndrome [10,79,80], or diabetes [5,81,82], future investigations should focus on developing models where the fibroblasts and the dentin are both modified. The gene discussed is TGFB1; the disease is diabetes mellitus.